Table 1.

Sigma-2 binding affinity and pancreatic cancer cell line viability, following sigma-2 receptor ligand treatment (24 h)

Cmpd	Affinity (K i, nM)	Activity (EC50, μM)
	σ2	Panc02	KP02	KCKO	MIAPaCa-2	BxPC3	AsPC-1	Panc-1
PB28a	0.68	43	>100	87	51	>100	>100	>100
PB221a	18.8	37	>100	19	50	100	>100	>100
PB183b	9.24	83	97	51	49	100	>100	>100
F281c	12.6	37	49	62	29	42	98	>100
PB282d	14.1	>100	>100	90	51	>100	>100	>100

^aSigma-2 binding data are from Berardi, et al. 2009 [26]; ^bSigma-2 binding data are from Berardi, et al. 2004 [25]; ^cSigma-2 binding data are from Ferorelli et al., 2007 [27]; ^dSigma-2 binding data are from Abate, et al., 2011 [28]. Pancreas cancer cell lines were treated with escalating doses of the sigma-2 ligands PB28, PB221, PB183, F281, PB282 or DMSO vehicle for 24 h and viability relative to vehicle determined by MTT Assay